PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
GeneMatrix swung to a quarterly operating and net profit in Q2 2026 on export growth, but on an annual basis it still faces a persistent operating loss structure and weakening balance sheet strength.
In Q2 2026, revenue reached KRW 2.91 billion with operating profit of KRW 390 million and net profit of KRW 689 million, marking the first simultaneous operating and net profit in five quarters.
Exports grew 96% year-on-year, with more than 40% of total revenue derived from exports of the NeoPlex product line.
Full-year 2025 revenue rose to KRW 10.64 billion year-on-year, with the operating margin improving to -6.4%, narrower than in 2022-2024.
Operating cash flow turned positive at KRW 1.29 billion in 2025, the first positive figure in the past four years.
Equity declined from KRW 24.19 billion in 2022 to KRW 17.47 billion in 2025, while the debt ratio rose from 31.9% to 56.1%, indicating some weakening in balance sheet strength.
Founded in 2000 out of research at Seoul National University College of Medicine and listed on KOSDAQ in 2009, GeneMatrix is a molecular diagnostics specialist. Built on its proprietary multiplex PCR platform, C-Tag, the company develops and sells infectious disease diagnostic reagents under the NeoPlex brand.
Its product portfolio spans sexually transmitted infections (STI), human papillomavirus (HPV), respiratory infections (RI), tuberculosis/non-tuberculous mycobacteria (TB/NTM), and gastrointestinal (GI) diagnostics.
The company also supplies blood-based biochemistry diagnostics and point-of-care test (POCT) products to diversify its customer base.
Overseas expansion has centered on distribution partnerships: in 2017 GeneMatrix signed a supply agreement with Italy's AB Analitica for STI diagnostic kits, and in 2024 it signed a global supply agreement with multinational in vitro diagnostics company ELITechGroup to integrate NeoPlex products with automated platforms.
Beyond diagnostics, the company maintains a new drug pipeline covering hepatitis A, Japanese encephalitis, shingles and COVID-19 vaccines, an HPV therapeutic vaccine, and immuno-oncology, though these remain pre-commercial with limited near-term revenue contribution.
Competition includes domestic molecular diagnostics peers such as Seegene as well as multinational in vitro diagnostics companies, and the company seeks differentiation through multiplex assay technology and expanding overseas distribution.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩2.7B | -₩90,715,551 | −3.4% |
| 2025Q3 | ₩2.6B | -₩100M | −4.2% |
| 2025Q4 | ₩2.9B | -₩200M | −6.7% |
| 2026Q1 | ₩2.5B | -₩300M | −13.0% |
| 2026Q2 | ₩2.9B | ₩400M | 13.5% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩11.2B | -₩1.5B | -₩8.1B | −13.6% | −33.5% | 31.9% |
| 2023 | ₩9.8B | -₩2.5B | -₩900M | −26.0% | −3.9% | 35.4% |
| 2024 | ₩10B | -₩1.6B | -₩3.7B | −16.4% | −19.5% | 48.0% |
| 2025 | ₩10.6B | -₩700M | -₩1.8B | −6.4% | −10.5% | 56.1% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Consolidated revenue reached KRW 10.64 billion in 2025, continuing an uptrend from KRW 10.02 billion in 2024 and KRW 9.81 billion in 2023, though still below the KRW 11.21 billion recorded in 2022.
The operating loss widened from KRW -1.52 billion in 2022 to KRW -2.55 billion in 2023, before narrowing to KRW -1.64 billion in 2024 and KRW -0.68 billion in 2025, with the operating margin improving from -13.6% to -26.0% to -16.4% to -6.4% over the period.
Net losses, by contrast, showed no consistent direction: a large loss of KRW -8.11 billion in 2022 narrowed to KRW -0.89 billion in 2023, widened again to KRW -3.75 billion in 2024, and registered KRW -1.83 billion in 2025.
On a quarterly basis from Q2 2025 through Q2 2026, revenue moved between KRW 2.69 billion, KRW 2.59 billion, KRW 2.87 billion, KRW 2.52 billion, and KRW 2.91 billion, while operating results showed losses of KRW -91 million, KRW -109 million, KRW -191 million and KRW -327 million before turning to a profit of KRW 393 million in Q2 2026.
Net results were even more volatile: in Q3 2025 the company posted a net profit of KRW 266 million despite an operating loss of KRW -109 million, while in Q4 2025 the net loss widened to KRW -923 million even though the operating loss was a smaller KRW -191 million, suggesting non-operating, one-off items may have been involved.
In Q1 2026 the operating loss widened further to KRW -327 million before a clear turnaround in Q2 2026, when revenue of KRW 2.91 billion produced an operating profit of KRW 393 million and a net profit of KRW 689 million.
On cash flow, operating cash flow remained negative at KRW -1.02 billion in 2022, KRW -2.35 billion in 2023 and KRW -0.20 billion in 2024 before turning positive at KRW 1.29 billion in 2025, tracking the improvement seen in the income statement.
Equity, however, declined steadily from KRW 24.19 billion in 2022 to KRW 17.47 billion in 2025 due to accumulated losses, while the debt ratio rose from 31.9% to 56.1% over the same period, indicating that balance sheet pressure has increased even as profitability metrics improved.
The domestic and global molecular diagnostics market has shifted its center of gravity toward multiplex testing for infectious diseases broadly as the COVID-19-related demand surge has faded.
While single-target COVID-19 testing demand has fallen sharply, ongoing demand persists for simultaneous multiplex testing of endemic infections such as sexually transmitted infections, respiratory illness, and tuberculosis, a backdrop relatively favorable to companies with multiplex diagnostic technology.
In Europe, tightened In Vitro Diagnostic Regulation (IVDR) requirements have raised certification barriers, which can benefit companies that already hold approvals; GeneMatrix has already obtained European certification for its NeoPlex product line.
On the competitive front, domestic molecular diagnostics specialists such as Seegene coexist with large multinational in vitro diagnostics companies including bioMérieux and ELITechGroup, and smaller players often pursue market entry through local partnerships rather than building their own distribution networks.
GeneMatrix follows a similar strategy, accessing the European market through its collaborations with AB Analitica and ELITechGroup while expanding supply contracts into emerging markets in Asia and Latin America.
GeneMatrix is also listed among the companies tracked by Korea Drug Development Fund (KDDF) as holding new drug pipelines, indicating the industry recognizes its research activity in vaccines and immuno-oncology beyond diagnostics.
However, a common feature across Korea's domestic new drug pipelines is that a large share remain at the discovery or pre-clinical stage, and GeneMatrix's drug development segment can be viewed as situated at this early phase of the industry cycle.
At the time of its Q2 2026 earnings release, the company stated that it expects the turnaround to profitability to continue, outlining plans to pursue export growth and sustained expansion through strengthened overseas competitiveness and country-specific marketing.
Reports indicate the company is also pursuing supply contract expansion into Asian and Latin American markets in addition to its established European distribution network, as part of a market diversification strategy.
The global supply agreement signed with ELITechGroup in 2024 aims to combine NeoPlex products with ELITechGroup's automated platform into an all-in-one diagnostic system, making the pace of contract execution a variable that could affect future export performance.
Under the regular disclosure schedule, the Q3 2026 report is due by the statutory filing deadline of November 16, 2026, which should provide additional data on whether the Q2 turnaround is a one-off event or part of a sustained trend.
The drug development pipeline, with vaccine candidates still at pre-clinical or early development stages, remains a medium- to long-term monitoring item rather than a near-term revenue driver.
Overall, the company's near-term outlook appears heavily dependent on whether export momentum continues and how quickly its European and emerging-market supply contracts are executed.
The current share price trades at a level that reflects a certain premium to net asset value, which can be interpreted as partly pricing in market expectations following the recent quarterly turnaround to profit.
On an annual basis, however, the company still operates within a cumulative net-loss structure, making it important to watch whether net income settles into a clear profitable trend going forward.
Dividend history has not been confirmed in recent periods, limiting the investment appeal from a dividend-yield perspective.
Looking at historical annual results, the steady improvement in operating margin from -26.0% in 2023 to -6.4% in 2025 is a notable trend, though the high volatility in quarterly net income means it is premature to draw firm conclusions from a single quarter's results.
How the valuation is interpreted going forward will likely depend on whether subsequent quarters replicate the Q2 2026 turnaround or prove to be a one-off event similar to Q3 2025.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
In Q2 2026, export revenue increased 96% year-over-year, driving simultaneous turnaround to operating profit and net profit. Overseas sales growth was observed across infectious disease diagnostic products overall, with HPV diagnostic product sales up 266% and STI product sales up 113%.
Over 40% of revenue was generated from Neoplex product line exports, indicating a structure that is evolving to not depend on any single market.
The operating loss ratio showed a trend of annual narrowing, from -26.0% in 2023 to -16.4% in 2024 and -6.4% in 2025. Operating cash flow also turned positive with an inflow of KRW 1.29 billion in 2025, showing that profit and loss improvement is translating into cash generation.
If this trend continues, there is room for additional profitability improvement through fixed cost leverage effects.
Supply agreements with Italy's AB Analitica and global in-vitro diagnostics company ELITechGroup have secured entry channels into the European market.
The collaboration with ELITechGroup aims to supply an all-in-one system combining Neoplex with an automation platform, and if the contract moves into full-scale implementation, expansion of distribution channels is expected. The multiplex diagnostic portfolio (STI, HPV, RI, TB/NTM, GI) is reducing dependence on a single product.
In Q3 2025, net profit was positive despite an operating loss, while in Q4, despite a relatively small operating loss, the net loss expanded to -KRW 920 million, indicating that one-time profit and loss factors significantly shook performance.
Such volatility makes it difficult to judge the sustainability of the Q2 2026 turnaround to profitability. At least one to two additional quarters of confirmation are needed.
Equity capital has declined for four consecutive years, from KRW 24.19 billion in 2022 to KRW 17.47 billion in 2025, while the debt ratio rose from 31.9% to 56.1% over the same period.
As accumulated net losses continue, there is pressure toward capital impairment, making the pace of capital recovery through future profit accumulation an important point to monitor.
The new drug pipeline in the vaccine and immuno-oncology fields remains at the preclinical or early development stage, making short-term revenue contribution difficult to expect.
As the domestic new drug development industry overall has a structure with a high proportion of early-stage projects, commercialization may take a long time. R&D expenditure continues while the timing of returns remains uncertain.
As the revenue structure shifts toward a significant portion being generated from overseas exports, performance may become sensitive to exchange rate fluctuations and changes in the inventory and ordering policies of overseas distribution partners.
If delays occur in fulfilling supply contracts in specific regions or if partner companies change, this could lead to sharp fluctuations in export performance.
In a market where domestic molecular diagnostics specialists such as Seegene coexist with global in-vitro diagnostics giants such as bioMérieux and ELITechGroup, price and technology competition continues.
Strengthened certification regulations such as IVDR may act as an entry barrier, but at the same time may also impose a burden in the form of certification maintenance and renewal costs.
As a small-cap KOSDAQ stock, share price volatility can be relatively high.
In July 2026, a large number of ownership change disclosure reports from executives and major shareholders were concentrated in submission, so it is necessary to continuously monitor related disclosures going forward to check for changes in the ownership structure.
Statutory filing deadline for the Q3 2026 report, which should provide key data on whether the Q2 turnaround to profit was one-off or trend-based.
Progress on the execution of the all-in-one diagnostic system supply agreement with ELITechGroup, and whether new supply contracts are signed in Asia or Latin America, warrant monitoring.
Check whether the divergence between operating and net profit (from one-off items) recurs, to assess the quality of earnings.
Monitor for disclosures related to pre-clinical or clinical progress in the vaccine and immuno-oncology pipeline, or any licensing-related news.
GeneMatrix produced a positive shift in its recent earnings trajectory, swinging to a simultaneous operating and net profit in Q2 2026 on the back of export growth.
On an annual basis, clues of structural improvement are also visible, with the operating margin narrowing steadily from -26.0% in 2023 to -6.4% in 2025 and operating cash flow turning positive in 2025.
However, quarterly net income has been highly volatile, with one-off items diverging from operating results in Q3 and Q4 of 2025, meaning further quarters of data are needed to confirm whether the Q2 2026 turnaround is trend-based.
At the same time, balance sheet pressure persists, with equity declining for four consecutive years and the debt ratio rising. The drug development pipeline remains at an early stage and is better viewed as a medium- to long-term item than a near-term earnings driver.
Investors may wish to track the durability of export momentum, the quality of earnings revealed in the Q3 2026 report, and trends in the company's financial structure.
Report written 2026-10-01 · Data as of 2026-09-30
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.